These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 29756386)
21. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846 [TBL] [Abstract][Full Text] [Related]
22. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009 [TBL] [Abstract][Full Text] [Related]
23. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178 [TBL] [Abstract][Full Text] [Related]
24. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. Chu NJ; Anders RA; Fertig EJ; Cao M; Hopkins AC; Keenan BP; Popovic A; Armstrong TD; Jaffee EM; Zimmerman JW Cancer Prev Res (Phila); 2020 Jul; 13(7):569-582. PubMed ID: 32409593 [TBL] [Abstract][Full Text] [Related]
26. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173 [TBL] [Abstract][Full Text] [Related]
27. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Ardito CM; Grüner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374 [TBL] [Abstract][Full Text] [Related]
28. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. Cruz VH; Arner EN; Du W; Bremauntz AE; Brekken RA JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938713 [TBL] [Abstract][Full Text] [Related]
29. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Carrière C; Gore AJ; Norris AM; Gunn JR; Young AL; Longnecker DS; Korc M Gastroenterology; 2011 Sep; 141(3):1091-101. PubMed ID: 21699781 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215 [TBL] [Abstract][Full Text] [Related]
31. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Thielman NRJ; Funes V; Davuluri S; Ibanez HE; Sun WC; Fu J; Li K; Muth S; Pan X; Fujiwara K; Dwayne L Thomas Ii ; Henderson M; Teh SS; Zhu Q; Thompson E; Jaffee EM; Kolodkin A; Meng F; Zheng L Sci Adv; 2024 Oct; 10(42):eadp0684. PubMed ID: 39413197 [TBL] [Abstract][Full Text] [Related]
32. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877 [TBL] [Abstract][Full Text] [Related]
33. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419 [TBL] [Abstract][Full Text] [Related]
34. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Schofield HK; Zeller J; Espinoza C; Halbrook CJ; Del Vecchio A; Magnuson B; Fabo T; Cali Daylan AE; Kovalenko I; Lee HJ; Yan W; Feng Y; Karim SA; Kremer DM; Kumar-Sinha C; Lyssiotis CA; Ljungman M; Morton JP; Galbán S; Fearon ER; Pasca di Magliano M JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367463 [TBL] [Abstract][Full Text] [Related]
35. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143 [TBL] [Abstract][Full Text] [Related]
36. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. Ray KC; Bell KM; Yan J; Gu G; Chung CH; Washington MK; Means AL PLoS One; 2011 Feb; 6(2):e16786. PubMed ID: 21311774 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Shibata W; Kinoshita H; Hikiba Y; Sato T; Ishii Y; Sue S; Sugimori M; Suzuki N; Sakitani K; Ijichi H; Mori R; Endo I; Maeda S Sci Rep; 2018 Apr; 8(1):6150. PubMed ID: 29670173 [TBL] [Abstract][Full Text] [Related]
38. [Significance of ras mutations in pancreatic diseases]. Löhr M; Liebe S; Lowenfels AB Z Gastroenterol; 1998 Oct; 36(10):929-32. PubMed ID: 9846373 [No Abstract] [Full Text] [Related]
39. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269 [TBL] [Abstract][Full Text] [Related]